Fig. 6

Antitumor effect of rGO/AgNC in vivo. A Daily reductions in Ehrlich ascites carcinoma (EAC) cells in the peritoneal exudate of mice treated with 10 mg/kg rGO/AgNC for 7 days, a week after initial 4 × 10⁶ EAC cell injection. B–D The nanocomposite reduces the ascites volume in EAC-bearing mice: B control mice, C mice injected initially with EAC cells, and D EAC-bearing mice treated daily with rGO/AgNC. E, F Restoration of the body weight and abdominal circumference in EAC-bearing mice after rGO/AgNC treatment. G Treatment with rGO/AgNC restores serum albumin level (ANOVA p < 0.05, * and # denote significantly different values, as determined by post hoc t-test, from the control and EAC-bearing group, respectively)